Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 296443 | 3.59 |
09:34 ET | 274939 | 3.835 |
09:36 ET | 199810 | 3.87 |
09:38 ET | 82414 | 3.75 |
09:39 ET | 36128 | 3.7001 |
09:41 ET | 21200 | 3.7 |
09:43 ET | 43683 | 3.605 |
09:45 ET | 50805 | 3.705 |
09:48 ET | 53374 | 3.755 |
09:50 ET | 16543 | 3.695 |
09:52 ET | 100524 | 3.63 |
09:54 ET | 174246 | 3.48 |
09:56 ET | 54411 | 3.35 |
09:57 ET | 62712 | 3.3566 |
09:59 ET | 127891 | 3.3606 |
10:01 ET | 297573 | 3.23 |
10:03 ET | 167552 | 3.245 |
10:06 ET | 129970 | 3.3712 |
10:08 ET | 114655 | 3.405 |
10:10 ET | 92232 | 3.435 |
10:12 ET | 21352 | 3.425 |
10:14 ET | 49509 | 3.42 |
10:15 ET | 32031 | 3.455 |
10:17 ET | 50738 | 3.475 |
10:19 ET | 43729 | 3.5 |
10:21 ET | 31068 | 3.51 |
10:24 ET | 154345 | 3.59 |
10:26 ET | 23534 | 3.69 |
10:28 ET | 21074 | 3.69 |
10:30 ET | 46877 | 3.735 |
10:32 ET | 84185 | 3.705 |
10:33 ET | 45447 | 3.775 |
10:35 ET | 25221 | 3.795 |
10:37 ET | 46928 | 3.71 |
10:39 ET | 17800 | 3.765 |
10:42 ET | 10039 | 3.725 |
10:44 ET | 11812 | 3.6601 |
10:46 ET | 33855 | 3.71 |
10:48 ET | 25323 | 3.6652 |
10:50 ET | 31621 | 3.755 |
10:51 ET | 29825 | 3.73 |
10:53 ET | 20237 | 3.7602 |
10:55 ET | 33222 | 3.725 |
10:57 ET | 33923 | 3.7003 |
11:00 ET | 17022 | 3.695 |
11:02 ET | 14021 | 3.71 |
11:04 ET | 13024 | 3.685 |
11:06 ET | 46431 | 3.645 |
11:08 ET | 38101 | 3.6112 |
11:09 ET | 44977 | 3.605 |
11:11 ET | 47030 | 3.66 |
11:13 ET | 59511 | 3.67 |
11:15 ET | 8190 | 3.655 |
11:18 ET | 9872 | 3.6212 |
11:20 ET | 9452 | 3.615 |
11:22 ET | 35532 | 3.585 |
11:24 ET | 7984 | 3.59 |
11:26 ET | 2000 | 3.595 |
11:27 ET | 34085 | 3.605 |
11:29 ET | 11959 | 3.605 |
11:31 ET | 24740 | 3.625 |
11:33 ET | 30688 | 3.665 |
11:36 ET | 20944 | 3.655 |
11:38 ET | 62919 | 3.69 |
11:40 ET | 22712 | 3.645 |
11:42 ET | 12329 | 3.6 |
11:44 ET | 26971 | 3.58 |
11:45 ET | 23750 | 3.56 |
11:47 ET | 9461 | 3.545 |
11:49 ET | 1400 | 3.54 |
11:51 ET | 16302 | 3.51 |
11:54 ET | 19784 | 3.53 |
11:56 ET | 31849 | 3.5101 |
11:58 ET | 5535 | 3.525 |
12:00 ET | 2227 | 3.53 |
12:02 ET | 41338 | 3.4909 |
12:03 ET | 14385 | 3.4799 |
12:05 ET | 8801 | 3.475 |
12:07 ET | 58957 | 3.4501 |
12:09 ET | 32364 | 3.455 |
12:12 ET | 64751 | 3.4101 |
12:14 ET | 54767 | 3.415 |
12:16 ET | 7782 | 3.405 |
12:18 ET | 1501 | 3.41 |
12:20 ET | 6571 | 3.4 |
12:21 ET | 22847 | 3.435 |
12:23 ET | 2664 | 3.44 |
12:25 ET | 7783 | 3.415 |
12:27 ET | 52601 | 3.415 |
12:30 ET | 12733 | 3.415 |
12:32 ET | 24682 | 3.425 |
12:34 ET | 14715 | 3.405 |
12:36 ET | 26295 | 3.395 |
12:38 ET | 18707 | 3.415 |
12:39 ET | 74479 | 3.39 |
12:41 ET | 115712 | 3.34 |
12:43 ET | 103259 | 3.32 |
12:45 ET | 62697 | 3.3301 |
12:48 ET | 14740 | 3.3301 |
12:50 ET | 14327 | 3.338 |
12:52 ET | 52139 | 3.345 |
12:54 ET | 6752 | 3.335 |
12:56 ET | 9386 | 3.34 |
12:57 ET | 4980 | 3.34 |
12:59 ET | 10802 | 3.345 |
01:01 ET | 24818 | 3.3701 |
01:03 ET | 82852 | 3.36 |
01:06 ET | 15131 | 3.345 |
01:08 ET | 7080 | 3.345 |
01:10 ET | 56126 | 3.315 |
01:12 ET | 43131 | 3.3208 |
01:14 ET | 1660 | 3.325 |
01:15 ET | 5988 | 3.325 |
01:17 ET | 10397 | 3.305 |
01:19 ET | 45050 | 3.3001 |
01:21 ET | 6263 | 3.305 |
01:24 ET | 55040 | 3.345 |
01:26 ET | 6694 | 3.335 |
01:28 ET | 2119 | 3.335 |
01:30 ET | 9034 | 3.345 |
01:32 ET | 86506 | 3.345 |
01:33 ET | 28191 | 3.305 |
01:35 ET | 7262 | 3.2901 |
01:37 ET | 22291 | 3.345 |
01:39 ET | 61857 | 3.36 |
01:42 ET | 14528 | 3.365 |
01:44 ET | 21901 | 3.34 |
01:46 ET | 14949 | 3.36 |
01:48 ET | 7069 | 3.35 |
01:50 ET | 100384 | 3.34 |
01:51 ET | 14951 | 3.34 |
01:53 ET | 16708 | 3.3398 |
01:55 ET | 40070 | 3.335 |
01:57 ET | 3598 | 3.335 |
02:00 ET | 23436 | 3.34 |
02:02 ET | 55613 | 3.3647 |
02:04 ET | 22394 | 3.35 |
02:06 ET | 3000 | 3.345 |
02:08 ET | 1775 | 3.34 |
02:09 ET | 4648 | 3.34 |
02:11 ET | 7897 | 3.335 |
02:13 ET | 4401 | 3.335 |
02:15 ET | 61389 | 3.295 |
02:18 ET | 15911 | 3.31 |
02:20 ET | 70221 | 3.2701 |
02:22 ET | 9363 | 3.2799 |
02:24 ET | 2567 | 3.275 |
02:26 ET | 83152 | 3.28 |
02:27 ET | 122915 | 3.225 |
02:29 ET | 63088 | 3.2301 |
02:31 ET | 9176 | 3.24 |
02:33 ET | 10462 | 3.245 |
02:36 ET | 71480 | 3.22 |
02:38 ET | 10463 | 3.2188 |
02:40 ET | 60783 | 3.245 |
02:42 ET | 3892 | 3.2466 |
02:44 ET | 12717 | 3.235 |
02:45 ET | 11944 | 3.25 |
02:47 ET | 18256 | 3.26 |
02:49 ET | 68915 | 3.301 |
02:51 ET | 24428 | 3.335 |
02:54 ET | 5746 | 3.315 |
02:56 ET | 16002 | 3.325 |
02:58 ET | 3606 | 3.32 |
03:00 ET | 6042 | 3.325 |
03:02 ET | 24079 | 3.315 |
03:03 ET | 2300 | 3.315 |
03:05 ET | 13307 | 3.315 |
03:07 ET | 4652 | 3.32 |
03:09 ET | 936 | 3.315 |
03:12 ET | 4056 | 3.315 |
03:14 ET | 6563 | 3.315 |
03:16 ET | 37237 | 3.315 |
03:18 ET | 211807 | 3.32 |
03:20 ET | 46941 | 3.345 |
03:21 ET | 17793 | 3.3492 |
03:23 ET | 1989 | 3.345 |
03:25 ET | 45281 | 3.375 |
03:27 ET | 74606 | 3.31 |
03:30 ET | 70692 | 3.325 |
03:32 ET | 6592 | 3.32 |
03:34 ET | 26964 | 3.315 |
03:36 ET | 2913 | 3.315 |
03:38 ET | 26247 | 3.32 |
03:39 ET | 6113 | 3.315 |
03:41 ET | 44413 | 3.335 |
03:43 ET | 10074 | 3.335 |
03:45 ET | 13272 | 3.335 |
03:48 ET | 17803 | 3.335 |
03:50 ET | 63656 | 3.34 |
03:52 ET | 42894 | 3.355 |
03:54 ET | 51735 | 3.3698 |
03:56 ET | 70538 | 3.37 |
03:57 ET | 65292 | 3.385 |
03:59 ET | 119900 | 3.38 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 2.4B | -20.4x | --- |
Janux Therapeutics Inc | 2.4B | -37.1x | --- |
Celldex Therapeutics Inc | 2.4B | -13.0x | --- |
CG Oncology Inc | 2.2B | -29.0x | --- |
MoonLake Immunotherapeutics | 2.6B | -54.5x | --- |
Intellia Therapeutics Inc | 2.4B | -4.6x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.33 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -20.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.